Intraprostatic Ethanol Diffusion: Comparison of Two Injection Methods Using Ex Vivo Human Prostates

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2015 Jul 15

PMID 26171881

Citations 2

Authors

B J King

T K Mann-Gow

M Kida

M K Plante

S D Perrapato

P Zvara

Affiliations

Soon will be listed here.

Abstract

Background: Intraprostatic injection of ethanol has been previously tested in clinical trials as a potential treatment of BPH, with variable outcomes. As evident from animal studies, the inconsistency was owing to various degrees of ethanol backflow along the needle tract. In acute canine experiments, we previously documented that using convection enhanced delivery (CED) eliminates backflow and improves ethanol distribution. The goal of this study was to compare the diffusion pattern between a microporous hollow fiber catheter (MiHFC) and a standard needle in human prostates from organ donors.

Methods: Prostates were harvested from cadaveric organ donors immediately after removal of organs for transplant. After trimming off excess fat and weighing, prostates were injected with absolute ethanol. The total injected volume was 25% of the calculated prostate volume. One lateral lobe was injected using a single lumen 21-gauge control needle. The contralateral lobe was injected with the same volume but using a MiHFC. Immediately after injection, prostates were fixed en bloc in 10% neutral-buffered formalin, and then sectioned. Three-dimensional reconstruction was performed to determine lesion volume based on hematoxylin- and eosin-stained cross-sections.

Results: Three fresh human prostates were harvested and injected. The time from harvest to intraprostatic injection was 15-35 min. The lesion created by the MiHFC was 1.14±0.52 cm(3), whereas that from the control needle was 0.28±0.10 cm(3) (P=0.038). No backflow was observed along the needle tract of the MiHFC.

Conclusions: This study shows that freshly harvested human prostates can be used to evaluate new treatments using intraprostatic injection. Similar to in vivo canine experiments, the ethanol lesion sizes were significantly bigger with the use of a MiHFC when compared with a standard single lumen needle.

Citing Articles

Tissue distribution of ethanol after intraprostatic injection using a porous needle.

Eubank M, Svihra Jr J, DiBona K, Sommers M, Oe T, Strnadel J Front Oncol. 2023; 12:1063781.

PMID: 36686794 PMC: 9846807. DOI: 10.3389/fonc.2022.1063781.

A pilot study in intraparenchymal therapy delivery in the prostate: a comparison of delivery with a porous needle vs standard needle.

Brady M, Coffield K, Kuehl T, Raghavan R, Speights Jr V, Patel B BMC Urol. 2018; 18(1):66.

PMID: 30055610 PMC: 6064133. DOI: 10.1186/s12894-018-0378-8.

References

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D . Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone. BJU Int. 2014; 114(6b):E32-E42. DOI: 10.1111/bju.12637. View

Bobo R, Laske D, Akbasak A, Morrison P, Dedrick R, Oldfield E . Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994; 91(6):2076-80. PMC: 43312. DOI: 10.1073/pnas.91.6.2076. View

Plante M, Gross A, Folsom J, Zvara P . Diffusion properties of transurethral intraprostatic injection. BJU Int. 2004; 94(9):1384-8. DOI: 10.1111/j.1464-410X.2004.05177.x. View

Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M . Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol. 2004; 46(4):496-501. DOI: 10.1016/j.eururo.2004.06.001. View

Goya N, Ishikawa N, Ito F, Ryoji O, Tokumoto T, Toma H . Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol. 1999; 162(2):383-6. View

Kovi J, Mostofi F, Heshmat M, Enterline J . Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer. 1988; 61(3):555-61. DOI: 10.1002/1097-0142(19880201)61:3<555::aid-cncr2820610322>3.0.co;2-h. View

Oh S, Odland R, Wilson S, Kroeger K, Liu C, Lowenstein P . Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg. 2007; 107(3):568-77. PMC: 2615393. DOI: 10.3171/JNS-07/09/0568. View

Oh S, Tsai A, Ohlfest J, Panoskaltsis-Mortari A, Vallera D . Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg. 2011; 114(6):1662-71. DOI: 10.3171/2010.11.JNS101214. View

Andersson K . Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2014; 25(1):12-8. DOI: 10.1097/MOU.0000000000000122. View

10.

Li Y, Zhao Q, Dong L . Efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia in patients with high-risk comorbidities: a long-term study at a single tertiary care institution. Urology. 2014; 83(3):586-91. DOI: 10.1016/j.urology.2013.10.071. View

11.

Plante M, Gross A, Kliment J, Kida M, Zvara P . Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int. 2003; 91(1):94-8. DOI: 10.1046/j.1464-410x.2003.04011.x. View

12.

LIEBERMAN D, Laske D, Morrison P, Bankiewicz K, Oldfield E . Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg. 1995; 82(6):1021-9. DOI: 10.3171/jns.1995.82.6.1021. View

13.

ANGELL J . Treatment of benign prostatic hyperplasia by phenol injection. Br J Urol. 1969; 41(6):735-8. DOI: 10.1111/j.1464-410x.1969.tb09986.x. View

14.

Andersson K . Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol. 2013; 47(2):83-90. DOI: 10.3109/00365599.2012.752404. View

15.

Pokorny M, de Rooij M, Duncan E, Schroder F, Parkinson R, Barentsz J . Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014; 66(1):22-9. DOI: 10.1016/j.eururo.2014.03.002. View

16.

Laske D, Morrison P, LIEBERMAN D, Corthesy M, Reynolds J, Koong S . Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg. 1997; 87(4):586-94. DOI: 10.3171/jns.1997.87.4.0586. View

17.

Talwar G, Pande S . Injection treatment of enlarged prostate. Br J Surg. 1966; 53(5):421-7. DOI: 10.1002/bjs.1800530510. View

18.

Ditrolio J, Patel P, Watson R, Irwin R . Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol. 2002; 167(5):2100-3; discussion 2103-4. View

19.

King B, Plante M, Kida M, Mann-Gow T, Odland R, Zvara P . Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. J Urol. 2012; 187(5):1898-902. PMC: 3730440. DOI: 10.1016/j.juro.2011.12.057. View

20.

Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M . Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2014; 67(4):787-94. DOI: 10.1016/j.eururo.2014.08.077. View